Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

CYCLACEL PHARMACEUTICALS INC
Mes dernières consult.
Most popular
Report
 SummaryNewsCalendarCompanyFinancialsConsensus 
Company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases.The company builds a diversified biopharmaceutical... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
11/13 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
11/09 CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
11/09 CYCLACEL PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/02 Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results
11/01 Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamles..
09/21 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare..
09/13 CYCLACEL PHARMACEUTICALS INC : Today's Research Reports on Trending Tickers: Cyc..
09/11 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
09/11 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
09/08 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Globa..
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts 0
Average target price 7,00 $
Spread / Average Target 274%
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC22
GILEAD SCIENCES1.16%94 196
REGENERON PHARMACEUTICALS6.67%41 388
VERTEX PHARMACEUTICALS100.10%36 580
GENMAB4.43%11 537
EXELIXIS, INC.76.93%7 589